Evidence map›Paper›PMID 32747678›Full record

ArticleScientific reports2020

The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients.

Qianqian Zeng, Jie Shen, Kangzhi Chen, Jinxia Zhou, Qiao Liao, Ke Lu, Jiao Yuan, Fangfang Bi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 6 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 6 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qianqian Zeng *Department of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China.
Jie Shen *Department of Neurology, The First Traditional Chinese Medicine Hospital, Changde, 415000, China.
Kangzhi Chen *Eight-Year Program of Clinical Medicine, Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Jinxia ZhouDepartment of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China.
Qiao LiaoDepartment of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China.
Ke LuDepartment of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China.
Jiao YuanDepartment of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China.
Fangfang BiDepartment of Neurology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha City, 410008, Hunan Province, China. fangfangbi@csu.edu.cn.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease accompanied with severe paralysis or even death, while the pathogenesis of ALS is still unclear and no effective therapy exists. The accumulating evidence has indicated the association between gut microbiota and various neurological diseases. Thus, to explore the potential role of gut microbiome in ALS, 20 patients diagnosed with probable or definite ALS and 20 healthy controls were enrolled and their fecal excrements were collected. The analysis of fecal community diversity with 16S rDNA sequencing showed an obvious change in microbial structure of ALS patients, where Bacteroidetes at the phylum level and several microbes at the genus level were up-regulated, while Firmicutes at the phylum level and Megamonas at the genus level were down-regulated compared to healthy controls. Additionally, decreased gene function associated with metabolic pathways was observed in ALS patients. The metagenomics further demonstrated the discrepancies in microflora at the species level and relevant metabolites thereof were also revealed when combined with metabolomics. In conclusion, the altered composition of the gut microbiota and metabolic products in ALS patients provided deeper insights into the pathogenesis of ALS, and these biomarkers might be established as potential therapeutic targets which deserve further exploration.

Indexed as

Gastrointestinal MicrobiomeAdultAmyotrophic Lateral SclerosisBacteroidetesCase-Control StudiesFemaleHumansMaleMetabolomicsMiddle AgedRNA, Ribosomal, 16SRNA, Ribosomal, 16S

Identifiers

PMID32747678
PMCPMC7398913
OpenAlexW3047107005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.